203 related articles for article (PubMed ID: 12225242)
21. Novel approaches to the pharmacotherapy of obesity.
Gouni-Berthold I; Brüning JC; Berthold HK
Curr Pharm Des; 2013; 19(27):4938-52. PubMed ID: 23278490
[TBL] [Abstract][Full Text] [Related]
22. Drug treatment of obesity: established and emerging therapies.
Isidro ML; Cordido F
Mini Rev Med Chem; 2009 Jun; 9(6):664-73. PubMed ID: 19519492
[TBL] [Abstract][Full Text] [Related]
23. Advances in anti-obesity therapeutics.
Fong TM
Expert Opin Investig Drugs; 2005 Mar; 14(3):243-50. PubMed ID: 15833056
[TBL] [Abstract][Full Text] [Related]
24. Do we need anti-obesity drugs?
Hainer V; Hainerová IA
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():8-20. PubMed ID: 23280861
[TBL] [Abstract][Full Text] [Related]
25. Interface between pharmacotherapy and genes in human obesity.
O'Connor A; Swick AG
Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227
[TBL] [Abstract][Full Text] [Related]
26. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
27. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological approaches to intervention.
Guy-Grand B
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S22-4. PubMed ID: 9130037
[TBL] [Abstract][Full Text] [Related]
29. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome.
Nisoli E; Carruba MO
Pharmacol Res; 2004 Nov; 50(5):453-69. PubMed ID: 15458765
[TBL] [Abstract][Full Text] [Related]
30. Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.
Maksimov ML; Svistunov AA; Tarasov VV; Chubarev VN; Ávila-Rodriguez M; Barreto GE; Dralova OV; Aliev G
Curr Pharm Des; 2016; 22(7):895-903. PubMed ID: 26648466
[TBL] [Abstract][Full Text] [Related]
31. New drug targets for the treatment of obesity.
Powell AG; Apovian CM; Aronne LJ
Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742
[TBL] [Abstract][Full Text] [Related]
32. New agents in development for the management of obesity.
Vincent RP; le Roux CW
Int J Clin Pract; 2007 Dec; 61(12):2103-12. PubMed ID: 17850307
[TBL] [Abstract][Full Text] [Related]
33. Updates on obesity pharmacotherapy.
Velazquez A; Apovian CM
Ann N Y Acad Sci; 2018 Jan; 1411(1):106-119. PubMed ID: 29377198
[TBL] [Abstract][Full Text] [Related]
34. An update in the management of obesity: the weight of CNS targets.
Bariohay B; Roux JA; Bonnet MS; Dallaporta M; Troadec JD
Recent Pat CNS Drug Discov; 2011 Sep; 6(3):164-80. PubMed ID: 21834783
[TBL] [Abstract][Full Text] [Related]
35. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
36. Natural Dietary and Herbal Products in Anti-Obesity Treatment.
Sun NN; Wu TY; Chau CF
Molecules; 2016 Oct; 21(10):. PubMed ID: 27727194
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical treatment of obesity.
Blackburn GL; Miller D; Chan S
Nurs Clin North Am; 1997 Dec; 32(4):831-48. PubMed ID: 9386228
[TBL] [Abstract][Full Text] [Related]
38. [Obesity: principles of drug therapy].
Imoberdorf R; Ballmer PE
Ther Umsch; 2000 Aug; 57(8):522-5. PubMed ID: 11026090
[TBL] [Abstract][Full Text] [Related]
39. Anti-Obesity Effects of Medicinal and Edible Mushrooms.
Ganesan K; Xu B
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400600
[TBL] [Abstract][Full Text] [Related]
40. Progress and challenges in anti-obesity pharmacotherapy.
Bessesen DH; Van Gaal LF
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):237-248. PubMed ID: 28919062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
